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Background: Abdominal aortic aneurysm (AAA) formation involves an inﬂammatory process with a strong genetic
background. C-reactive protein (CRP) regulates inﬂammation and is elevated in patients with AAA. The aim of this study
was to investigate the association of the triallelic (C, A, and T alleles) rs3091244 functional CRP single nucleotide
polymorphism (SNP) with AAA.
Methods: This was a case-control study involving two independent populations: 351 AAA patients (mean aortic diameter,
6.256 1.47 cm) and 391 controls (mean diameter, 2.46 0.2 cm) were recruited from Greece (the main cohort); and 371
patients (mean diameter, 5.4 6 1.0 cm) and 362 controls (mean diameter, 2.4 6 0.6 cm) were recruited from the United
Kingdom (replication cohort). The frequency of the functional triallelic (C, T, and A alleles) rs3091244 polymorphism
was analyzed in univariate and adjusted (for cardiovascular risk factors) analyses, assuming that the rare T and A alleles
have similar functional properties (pooled analysis for T and A). Three groups were constructed: group A included those
with the rare T and A alleles (genotypes TT, AA, and TA), group B included heterozygotes for the C allele (CT, CA), and
group C included C allele homozygotes (CC, reference genotype). Finally, meta-analysis of the two populations was
performed together with previously reported results.
Results:Genotype distributions differed signiﬁcantly between cases and controls in both cohorts (P < .001 and P[ .001).
Adjusted analysis (for all aneurysm-related risk-factors) showed an estimated odds ratio of 4.88 (95% conﬁdence interval
[CI], 2.96-8.04) for SNP group A and 2.38 (95% CI, 1.69-3.36) for SNP group B (P < .001 in both cases) in the initial
cohort and 2.07 (95% CI, 1.33-3.21) for SNP group A and 1.70 (95% CI, 1.21-2.39) for SNP group B (P [ .001 and
.002) in the replication cohort. The SNP group A patients among the main cohort also had higher CRP levels (median,
26; interquartile range, 17-52 mg/L vs median, 4; interquartile range, 4-12 mg/L; P < .001). Aneurysms >5.5 cm were
signiﬁcantly more frequent among the SNP groups A and B compared with C allele homozygotes both in the main and
the replication cohorts (P < .001 and P [ .001, respectively). Meta-analysis of the two populations with previously
reported results showed a positive association between minor-allele and aneurysm presence with an odds ratio of 1.47
(95% CI, 1.01-2.14; I2 [ 83.1%; P [ .04).
Conclusions: The rare T and A alleles were signiﬁcantly related with AAA presence in both populations and correlated with
higher CRP levels and AAA diameter. (J Vasc Surg 2014;60:1332-9.)
Clinical Relevance: Abdominal aortic aneurysm (AAA) constitutes a signiﬁcant health problem. Several environmental
factors are implicated, but the disease is recognized to have a strong genetic component. Those with a ﬁrst-degree relative
with AAA have up to an 11-fold increased risk of developing the disease themselves. This study identiﬁes a novel genetic
marker that was strongly correlated with AAA presence and size. This may help identify those at risk of developing an
AAA, especially of a large diameter. Additionally, the fact that this marker was correlated with raised C-reactive protein
levels, points toward a strong inﬂammatory process underlying AAA formation.Abdominal aortic aneurysm (AAA) constitutes a signif- environmental factors are implicated in the formation of
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an 11-fold increased risk of developing the disease them-
selves.6 Previous reports have investigated functional and
nonfunctional single nucleotide polymorphisms (SNPs) in
patients with aneurysmal disease.4,7 However, the majority
of the available literature has largely included patients with
small aneurysms from nongeographically uniform popula-
tions and ﬁndings have not been validated in separate
cohorts. Other investigators have followed a genome-
wide approach to identify potential genome targets. The
reported odds ratios (ORs) for the identiﬁed risk alleles
in these studies are not in agreement with the strong heri-
tability pattern observed in epidemiologic studies and
suggest that there are multiple risk loci associated with
the disease with many yet to be identiﬁed.8,9
C-reactive protein (CRP) levels have been linked to
cardiovascular disease prevalence.10,11 Additionally, CRP
is known to induce the production of nitric oxide, regulate
ﬁbrinolysis, and alter the expression of inﬂammatory mole-
cules and complement.11,12 These processes have been
directly linked to AAA formation.13 Previous investigators
have attempted to link circulating levels of CRP with
speciﬁc genetic polymorphisms.14-16 A triallelic SNP
(alleles C, T, and A) known as rs3091244 has been shown
to independently correlate strongly with serum CRP levels
and cardiovascular risk.15,16 The C allele is associated with
low levels of CRP. The rare T and A alleles are both asso-
ciated with high levels of CRP.17 A recent study attempted
to assess the prevalence of this SNP in patients with an
AAA, documenting no signiﬁcant differences between
subjects and controls; however, this analysis included
patients with mostly small aneurysms, and the ﬁndings
have not been conﬁrmed in independent populations.14
The present case-control study investigates the role of
the functional CRP polymorphism rs3091244 within
the promoter region of the CRP gene in the formation
of an AAA using two well characterized independent
populations.
METHODS
Study populations
This is a case control study including two geographi-
cally discrete populations. The main population of the
study is a group of patients undergoing endovascular or
open repair of an infrarenal AAA between January 2008
and April 2011 in a tertiary referral center for general
and vascular surgery in Northern Greece (cases) and
a group of geographically matched controls with similar
characteristics, without an AAA (maximal aortic diameter
of 3.0 cm), recruited within the same time period from
the same department. All individuals had provided written
informed consent for participation in the study. All relevant
clinical information (demographics, medication, medical
history, family history, abdominal imaging) was prospec-
tively recorded in an electronic registry. Both groups
were Caucasian whites of Mediterranean origin. Patients
with an AAA were eligible for repair if they had maximalaortic diameter >5 cm; maximal aortic diameter <5 cm
with a rapidly increasing sac (exceeding 1 cm per year);
and a symptomatic AAA. Patients with inﬂammatory aneu-
rysms or soft-tissue pathologies (Marfan’s syndrome or
other pathology related with aneurysmatosis) were
excluded. Control subjects were recruited from the same
general surgical department and consisted of patients
who had been admitted with an acute abdomen and had
already undergone imaging of their abdominal aorta
(computed tomography or arterial duplex) within the last
2 weeks before recruitment, documenting a maximal aortic
diameter <3.0 cm. They were all consecutive patients of
Greek origin. Patients with any aneurysm or soft-tissue
disease were excluded from this group. No further exclu-
sion criteria were applied. The study was approved by the
institutional ethics committee.
A second group of patients and controls (validation
cohort) from the United Kingdom was used to replicate
the initial ﬁndings of the main study cohort. Samples
were recruited from the Leicestershire regional screening
program and the inpatient and outpatient populations
of the Leicester regional Vascular Surgical Unit. The
control group were screened for AAA by ultrasound
(diameter <3.0 cm) and were all over 65 years of age
but not selected in any other way. The patients and
controls included in this study were consecutive individuals
with adequate genetic material and available baseline
demographics. No further exclusion criteria were applied.
Recruitment took place from 2002 to 2008. Clinical infor-
mation was gathered by participant interview upon recruit-
ment. The majority of the individuals recruited were of
British descent.
Genetic analyses
DNA extraction. Peripheral venous blood was drawn
into 5-mL ethylenediaminetetraacetic acid tubes upon
recruitment and stored at 80 C until DNA was extracted
using the QuickGene-810 system (Fujiﬁlm, Singapore).
Resulting DNA samples were stored at 4C until analysis.
Quality control for each batch of extractions was per-
formed by running a blank tube through the whole
process, omitting only the addition of blood. If any DNA
was found in the blank tube, the whole DNA batch was
rejected. Subject samples were identiﬁed by sample iden-
tiﬁcation numbers, and clinical data were not available
during genotyping.
Genotyping. The rs3091244 SNP was identiﬁed
using LightSNip (TIB MOLBIOL GmbH, Berlin,
Germany) on the Roche LightCycler 480 system (Roche
Diagnostics Corporation, Indianapolis, Ind), which is
based on real-time polymerase chain reaction and melting
curve analysis. The reaction mixture contained 7.2 mL of
polymerase chain reaction grade water, 0.5 mL of reagent
mix (primers and probe), 1.0 mL of FastStart DNA Master
and 0.8 mL of magnesium chloride (25 mM); 1.0 mL of
DNA was used. The LightCycler 480 instrument was
programmed as follows. Denaturation: 1 cycle at 95C for
10 minutes, ramp rate (C/s) 4.4, and acquisition mode
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4.4, and acquisition mode none; 60C for 10 seconds, ramp
rate 2.2, and acquisition mode single; and 72C for
15 seconds, ramp rate 4.4, and acquisition mode none.
Melting curve: 1 cycle at 95C for 30 seconds, ramp rate
4.4, and acquisition mode none; 40C for 2 minutes, ramp
rate 1.5, and acquisition mode none; and 75C for 0 seconds
with continuous acquisition mode and 3 acquisitions per
C. Cooling: 40C for 30 seconds with a ramp rate of 1.5.
The melting peaks were 55C for C allele, 59C for T allele,
62C for A allele, and 57C for heterozygous C/T.
Serum CRP quantiﬁcation and biochemical anal-
yses. All biochemical analyses for the main cohort (cases
and controls from Greece) were performed at baseline at
the institution where the patients were recruited, prior to
the repair of the AAA (part of preoperative assessment).
Serum CRP levels were measured using nephelometry
(Image 800 analyzer; Beckman Coulter, Brea, Calif).
Full-blood count and white cell count were measured
using a validated fully automated analyzer (CELL-DYN
Sapphire analyzer; Abbott Laboratories, Abbott Park, Ill).
Data were entered prospectively in an electronic database.
Serum CRP levels or other baseline biochemistry results
were not available for the second cohort (replication
group) of the study, recruited from the United Kingdom.
Meta-analysis
A systematic electronic search of the literature was per-
formed using the PubMed and Embase databases in
December 2012. The following terms were used: “abdom-
inal aortic aneurysm,” “C-reactive protein,” and “polymor-
phism.” Only one article was identiﬁed that had previously
investigated the rs3091244 polymorphism in individuals
with and without AAA. Subsequently, results from this
study, together with the results from our two cohorts
were meta-analyzed to assess the overall effect of the
SNP in AAA presence.
Statistical analysis
Analyses were performed using the Statistical Package
for Social Sciences v. 17.0 (SPSS, Chicago, Ill). Deviation
from the Hardy-Weinberg equilibrium was calculated using
the c2 test for all study populations. Continuous normally
distributed data are presented as mean value 6 standard
deviation, non-normally distributed data are presented as
median and interquartile range (IQR), and categorical
data are presented as absolute values and percentages.
Differences between cases and controls at baseline were
evaluated using Pearson’s c2 test for categorical variables
and Student t-test for continuous variables. With regards
to analyses of the triallelic rs3091244 SNP, we collapsed
the rare T and A alleles because of their identical functional
properties, as in previous studies18-20 and used the CC
genotype as the reference genotype. Three SNP groups
were constructed; group A included those bearing the
rare T and A alleles (genotypes AA, TT, and TA), group
B included heterozygotes for the C allele (CT, CA), and
group C included C allele homozygotes (CC, referencegenotype). Baseline differences between SNP groups A,
B, and C for continuous normally distributed variables
were evaluated using one-way analysis of variance and the
Kruskal-Wallis test for non-normally distributed variables.
Adjusted analyses (logistic regression) were performed
using all established AAA risk-factors21: age, sex, smoking,
hypertension, history of myocardial infarction (MI), hyper-
cholesterolemia, and diabetes, to assess the effect of the
rs3091244 genotype on AAA presence. Correlation
between aortic size and CRP concentration was tested using
Spearman rank correlation coefﬁcient. To meta-analyze the
data from the two geographically discrete populations
together with the results reported by Badger et al,14 we
used a random-effects model and calculated the random-
summary OR with a 95% conﬁdence interval (CI), by using
inverse-variance method. Meta-analysis was performed
using R version 2.15 for Windows. Heterogeneity was
assessed by using the I2 statistic and Cochrane Q test. A P
value of < .05 was considered signiﬁcant. Initial power
calculations to assess the necessary size of the populations
was based on the minor-allele frequencies observed in the
main study cohort (0.25 and 0.44) during the pilot stage
of the study and a power of at least 90% with an a of 0.05
was chosen. The size of the main cohort was sufﬁcient to
detect differences at a 5% (a ¼ .05) signiﬁcance level with
99% power and the size of the replication cohort was sufﬁ-
cient to detect differences with 75% power (a ¼ .05).RESULTS
The main study cohort included 351 patients with an
AAA (29 females [8%], mean age, 69 6 8 years; mean
aortic diameter, 6.25 6 1.47 cm) and 391 controls (64
females [16%], mean age, 73 6 5 years, mean aortic diam-
eter, 2.4 6 0.2 cm), all of Greek origin. No deviation from
the Hardy-Weinberg equilibrium was noted in either
patients or controls (c2 test; P ¼ .69 and .06, respectively).
Table I summarizes baseline characteristics for the
main cohort and Table II summarizes the prevalence of
AAA among the three different SNP groups. The minor
T and A alleles were signiﬁcantly more common among
those with aneurysmal disease (OR, 2.15; 95% CI, 1.73-
2.67; P < .001) (Table II). Logistic regression analysis,
adjusted for age, sex, smoking, hypertension, hypercholes-
terolemia, history of MI, and diabetes showed an estimated
OR of 4.88 (95% CI, 2.96-8.04) for SNP group A and
2.38 (95% CI, 1.69-3.36) for SNP group B (P < .001 in
both cases) with regards to AAA presence in the main
cohort (Tables III and IV). The SNP group A patients
had signiﬁcantly higher CRP levels, compared with hetero-
zygotes and homozygotes for the C allele (median, 26;
IQR, 17-52 mg/L vs median, 4; IQR, 3-12 mg/L; P <
.001; Table V), within the AAA group. The size of the
AAA was also correlated with baseline serum CRP levels
within the AAA group (Spearman’s rho correlation coefﬁ-
cient, 0.317; P < .001). Aneurysms with a diameter
>5.5 cm were signiﬁcantly more frequent among the
SNP group A (Table VI). In fact, 48% of patients with an
Table II. Genotype distributions of the triallelic rs3091244 C-reactive protein (CRP) single nucleotide polymorphism
(SNP) in the two study cohorts (univariate analysis)
Cohort 1 Cohort 2
Cases Controls Cases Controls
Minor allele frequency 0.44 0.25 0.48 0.38
Genotype Cases, % Controls, % P Cases, % Controls, % P
SNP group A (TT, AA, TA) 20 9
<.001
22 15
.001SNP group B (CT, CA) 47 33 52 46
SNP group C (CC) 33 58 26 39
Table I. Baseline characteristics and comparisons for each group
Cohort 1 (Greece)
P
Cohort 2 (United Kingdom)
PCases Controls Cases Controls
No. 351 391 - 371 362 -
Females 29 (8) 64 (16) .001 24 (7) 17 (5) .35
Age, years 69 6 8 73 6 5 <.001 72 6 7 71 6 7 .04
Aortic diameter, cm 6.25 6 1.47 2.4 6 0.2 <.001 5.4 6 1 2.4 6 0.6 <.001
Aortic diameter >5.5 cm 252 (72) - - 161 (43) - -
Symptomatic AAA 13 (4) - - - - -
Smoking history 257 (73) 311 (80) .08 326 (90) 302 (85) .04
Hypertension 271 (77) 300 (77) .87 187 (52) 178 (50) .83
Hypercholesterolemia 161 (46) 156 (40) .10 226 (63) 189 (53) .03
Statin use 205 (59) 213 (55) .28 - - -
Diabetes 77 (22) 88 (23) .85 58 (16) 52 (15) .64
COPD 31 (9) 42 (11) .38 - - -
PAD 72 (21) 70 (18) .37 - - -
MI 35 (10) 45 (12) .55 106 (30) 61 (17) <.001
AAA, Abdominal aortic aneurysm; COPD, chronic obstructive pulmonary disorder; MI, myocardial infarction; PAD, peripheral arterial disease; SD, standard
deviation.
Continuous data are presented as mean 6 standard deviation and categoric data as number (%).
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to 27% of those with an AAA <5.5 cm (P < .001).
The second cohort (replication group, from the
United Kingdom) included 371 patients with an AAA
(24 females [7%], mean age, 72 6 7 years; mean aortic
diameter, 5.4 6 1 cm) and 362 controls (17 females
[5%]; mean age, 71 6 7 years; mean aortic diameter,
2.4 6 0.6 cm) (Table I). These were predominantly white
Caucasians of British origin. No deviation from the
Hardy-Weinberg equilibrium was noted in this population
(c2 test; P ¼ .39 and .26 respectively). The minor T and A
alleles were signiﬁcantly more common among those with
aneurysmal disease (OR, 1.47; 95% CI, 1.19-1.81; P ¼
.001; Table II). Logistic regression analysis adjusted for
age, sex, smoking, hypertension, hypercholesterolemia,
history of MI, and diabetes showed an estimated OR of
2.07 (95% CI, 1.33-3.21) for SNP group A and 1.70
(95% CI, 1.21-2.39) for SNP group B (P ¼ .001 and
.002) with regards to AAA presence in the replication
cohort. Serum CRP levels were not available for this
cohort. Aneurysms with a diameter >5.5 cm were again
more frequent among the SNP groups A and B(Table VI). Combined univariate analysis of the two
cohorts (Greece and United Kingdom) showed that aneu-
rysms >5.5 cm in diameter were more frequent among
SNP groups A and B (P < .001).
Meta-analysis of the two populations together with
the results reported by Badger et al14 disclosed a positive asso-
ciationwith regards to aneurysmpresencewith anORof 1.47
(95% CI, 1.01-2.14; I2 ¼ 83.1%; P ¼ .04; Fig; Table VII).
DISCUSSION
This case control study suggests that the triallelic CRP
gene polymorphism rs3091244 may be related with the
presence of an AAA in two geographically discrete popula-
tions, which is in contrast with previous ﬁndings.14 Addi-
tionally, homozygotes for the rare T and A alleles in this
analysis had signiﬁcantly higher levels of CRP, supporting
previous data that the polymorphism is indeed func-
tional.15,16,18 Signiﬁcance was maintained after meta-
analysis of the two populations together with previously
reported results.14
The pathophysiology of AAA formation is multifactorial,
but there is strong epidemiologic evidence to suggest that
Table III. Logistic regression analysisemain cohort
(cohort 1)
Parameter OR 95% CI P
SNP group C (CC) genotype reference
SNP group A (TT, AA, TA) 4.877 2.957-8.043 <.0001
SNP group B (CT, CA) 2.379 1.687-3.355 <.0001
Age .908 0.885-0.931 <.0001
Sex 2.101 1.256-3.514 .005
Smoking history .749 0.517-1.085 .126
Hypercholesterolemia 1.655 1.191-2.299 .003
Hypertension 1.143 0.777-1.681 .499
Diabetes .979 0.667-1.436 .913
Myocardial infarction .847 0.506-1.417 .528
CI, Conﬁdence interval; OR, odds ratio; SNP, single nucleotide
polymorphism.
Table IV. Logistic regression analysisereplication
cohort (cohort 2)
Parameter OR 95% CI P
SNP group C (CC) genotype reference
SNP group A (TT, AA, TA) 2.067 1.332-3.207 .001
SNP group B (CT, CA) 1.702 1.214-2.388 .002
Age 1.011 0.990-1.033 .300
Sex .738 0.370-1.472 .389
Smoking history 1.456 0.915-2.315 .113
Hypercholesterolemia 1.060 0.868-1.296 .567
Hypertension .993 0.730-1.350 .964
Diabetes .973 0.635-1.490 .899
Myocardial infarction 1.850 1.283-2.668 .001
CI, Conﬁdence interval; OR, odds ratio; SNP, single nucleotide
polymorphism.
Table V. C-reactive protein (CRP) levels and associated
characteristics per genotype group (main cohort)eonly
for patients with abdominal aortic aneurysm (AAA)
Genotype Mean SD P
Age, years SNP group A: TT,
AA, TA
72 8
.08SNP group B: CT, CA 70 7
SNP group C: CC 72 6
Aortic diameter,
cm
SNP group A: TT,
AA, TA
6.74 1.51
.007SNP group B: CT, CA 6.16 1.49
SNP group C: CC 6.10 1.35
Urea, mg/dL SNP group A: TT,
AA, TA
5.5 3.4
.75SNP group B: CT, CA 5.2 3.5
SNP group C: CC 5.2 2.6
Hemoglobin,
g/dL
SNP group A: TT,
AA, TA
13.1 2.0
.44SNP group B: CT, CA 13.1 1.8
SNP group C: CC 12.8 1.9
Serum creatinine,
mg/dL
SNP group A: TT,
AA, TA
1.1 0.4
.43SNP group B: CT, CA 1.3 1.5
SNP group C: CC 1.2 1.0
White blood cell
count
SNP group A: TT,
AA, TA
8.7 4.6
.69SNP group B: CT, CA 8.7 2.5
SNP group C: CC 9.0 3.5
Body mass index,
kg/m2
SNP group A: TT,
AA, TA
28 5
.34SNP group B: CT, CA 28 5
SNP group C: CC 27 5
Genotype Median IQR P
CRP, mg/L SNP group A: TT, AA, TA 26 17-52
<.001SNP group B: CT, CA 4 3-12
SNP group C: CC 4 3-12
IQR, Interquartile range; SD, standard deviation; SNP, single nucleotide
polymorphism.
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examination of 73,451 individuals with no previous history
of AAA, Lederle et al22 found family history to be one of
the best predictors of AAA presence with an OR of 1.95
(95% CI, 1.56-2.43). Additionally, individuals with a ﬁrst-
degree relative with AAA may have up to an 11-fold
increased risk of developing an AAA.6 As a result, several
investigators assessed functional and nonfunctional SNPs
in patients with an AAA,4,7 aiming to elucidate the genetic
background of the disease. However, the majority of the
available literature has largely included patients with small
aneurysms, recruited from aneurysm screening programs,
resulting in poorly characterized populations with regards
to phenotype and associated risk-factor. Additionally, most
ﬁndings have not been validated in independent cohorts.
Other investigators have followed a genome-wide approach
to identify potential genome targets; however, the reported
ORs for the various identiﬁed risk alleles are not in agree-
ment with the strong heritability pattern observed in epide-
miologic studies, suggesting that there are multiple risk loci
associated with the disease.8,9
CRP levels have been related to cardiovascular disease
prevalence and outcomes in several populations.10,11 There
is evidence that CRP may be implicated in inducing nitric
oxide production, inhibit ﬁbrinolysis, and alter theexpression of the complement, processes involved in athero-
matosis and aneurysm formation.11,12 Powell et al23 were
among the ﬁrst to suggest a direct link between CRP levels
and AAA presence, comparing 20 patients undergoing elec-
tive AAA repair and 20 controls with aortoiliac occlusive
disease.23 Vainas et al24 measured highly sensitive CRP
(hsCRP) in 39 patients with AAA and also detected CRP
messenger RNA (mRNA) in the aneurysmal tissue of 16
patients. Serum hsCRP was associated with AAA presence
and hsCRP levels correlated signiﬁcantly with aortic size.
CRP mRNA was found in 25% of aneurysmal aortic tissues,
suggesting that CRP may be produced directly from the
AAA. A meta-analysis of six studies comparing serum CRP
levels between patients with AAA and controls (744 cases
with AAA and 1288 controls without AAA) demonstrated
signiﬁcantly higher CRP concentration among the AAA
group (pooled standardized mean difference: 0.50; 9% CI,
0.09-0.91; P ¼ .02).25
Carlson et al17 performed a systematic survey of the
common nucleotide variations across the CRP gene and
Table VI. Frequency of genotypes per aortic diameter (main and replication cohorts)
Cohort 1 Cohort 2
<5.5 cm, % 5.5-6.4 cm, % >6.5 cm, % <5.5 cm, % 5.5-6.4 cm, % >6.5 cm, %
SNP group A (TT, AA, TA) 27 25 48 66 19 15
SNP group B (CT, CA) 44 32 24 59 27 14
SNP group C (CC) 47 33 21 76 16 8
SNP, Single nucleotide polymorphism.
c2: P < .001 and P ¼ .01, respectively.
Fig. Forest plot representing the three populations included in the meta-analysis of the triallelic C-reactive protein
(CRP) polymorphism rs3091244 with regards to abdominal aortic aneurysm (AAA) presence. CI, Conﬁdence interval;
OR, odds ratio.
Table VII. Combined analysis of genotype distributions
of the triallelic rs3091244 C-reactive protein (CRP)
single nucleotide polymorphism (SNP) in the two study
cohorts and previously reported results
Study group OR 95% CI P
Main cohort (Greece) 2.15 1.73-2.67 <.001
Replication cohort (UK) 1.47 1.19-1.81 .001
Badger et al14 1.03 0.85-1.24 .829
Combined analysis 1.47 1.01-2.14 .047
CI, Conﬁdence interval; OR, odds ratio; UK, United Kingdom.
Random effects model used, I2 ¼ 83.1%.
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analysis revealed that the single most important SNP was
the triallelic rs3091244. The C allele was associated with
low levels of CRP. The rare T and A alleles were both asso-
ciated with high levels of CRP. Various other studies have
conﬁrmed these ﬁndings with regards to the T and A
alleles.15,16,19,20
Badger et al14 have studied the rs3091244 SNP in rela-
tion to AAA presence using 227 individuals with an AAA
and 277 controls. There was no statistical difference with
regards to genotype between cases and controls at univar-
iate analysis. No difference in CRP levels was demonstrated
for each genotype. However, these results have not been
validated in other populations, the number of patients
included in the study was fairly small, the study did not
analyze the minor T and A alleles combined (which have
identical functional properties), and the AAA groupincluded patients with small aneurysms (3.0-5.5 cm in
diameter). Including a large amount of patients with an
AAA close to 3.0 cm in diameter means that a signiﬁcant
proportion of that population may never develop an AAA
that will require treatment; therefore, it is not of much clin-
ical relevance. Additionally, by using a cut-off of 3.0 cm,
a proportion of the control population may have an aorta
close to 3.0 cm in diameter that may become aneurysmal
in the future. This can be controlled by including larger
AAAs in the study population.
The results of the current analysis are in contrast with
these ﬁndings. Adjusted regression analysis showed an esti-
mated OR of 4.90 (95% CI, 2.98-8.08) for those bearing
the rare T and A alleles and 2.37 (95% CI, 1.68-3.34) for
C allele heterozygotes (P< .001 in both cases) with regards
to AAA presence. Similar ﬁndings were seen in the validation
cohort, consisting of individuals from a different geographic
region. It is interesting to note that both populations, even
though they do derive from different geographical regions,
are of European origin, which may be considered as a limita-
tion of the study. However, the two cohorts did differ with
regards to key characteristics that could be implicated in
AAA formation and pose confounding factors in our anal-
yses. More speciﬁcally, the second cohort of patients with
aneurysmal disease consists (Table I) of slightly older
patients with signiﬁcantly higher rates of smoking and
smaller AAAs. The rate of smoking history in the ﬁrst cohort
was actually low (73%; Table I). The recruitment protocol
was also different, with those in the ﬁrst cohort having
been recruited after referral for surgical management and
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nantly from a screening program. We also documented
that homozygotes for the rare T and A alleles have signiﬁ-
cantly higher CRP levels, which is in accordance with
previous ﬁndings, suggesting that the rs3091244 SNP is
indeed functional. Patients with larger aneurysms in the ﬁrst
cohort also had higher CRP levels. There may be an associa-
tion with AAA growth and the SNP analyzed in this study;
however, these higher levels of CRP among individuals
with larger aneurysmal volumes may be secondary to the
presence of a larger inﬂammatory inﬁltrate. The only way
to investigate this etiologic role would be a study that follows
up patients to assess AAA growth rates. Also, in our second
cohort, most minor-allele homozygotes actually had an
AAA of <5.5 cm (Table VI).
The main value, from a clinical standpoint, of this SNP
is possibly not that of a “genetic screening marker.” The
minor-alleles are not very infrequent in the control popula-
tions (minor-allele frequencies of 0.44 vs 0.25 for cohort 1
and 0.48 vs 0.38 for cohort 2). This data mostly suggests
that inﬂammation plays a key role in AAA formation, and
there may be a genetic predisposition, partly related to
the SNP that has been investigated here that drives this.
Medication that targets this inﬂammatory process may be
of crucial importance in AAA management in the future.
Limitations. This analysis bears some limitations that
need to be mentioned. The second group of patients (vali-
dation cohort) was not prospectively recruited and CRP
levels or other baseline biochemistry results were not avail-
able to replicate our initial biochemical ﬁndings. Addition-
ally, aneurysmal tissue was not available to measure the
levels of CRP mRNA and assess whether CRP was being
produced directly by the AAA, which has been suggested
in previous studies. Also, the two populations included in
the study, even though they derive from two discrete
geographical areas (Greece and United Kingdom), are
both European. It would be of interest to further investi-
gate the speciﬁc SNP in non-European populations.
CONCLUSIONS
Overall, this study suggests that the T and A alleles were
related with AAA presence in two independent populations.
Additionally, they correlated with higher CRP levels and
AAA diameter. Further studies are required to validate
these ﬁndings and elucidate the exact role of CRP and
the speciﬁc polymorphism in AAA pathophysiology.
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